Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2010

View Archived Issues

Flibanserin improves HSDD symptoms in premenopausal women

Schering-Plough discloses new TNF-alpha production inhibitors

Biotie Therapies and Wyeth identify novel PDE inhibitors

Gruenenthal presents new bradykinin B1 receptor antagonists

UCB claims novel PI3K inhibitors

Diagnostic/prognostic gene expression signature identified for UCC

Regulus obtains license to microRNA-21 intellectual property

KB-001 shows clinical promise in P. aeruginosa infection

HRH1 gene SNP may predict response to OFC in depressed individuals

Gilead Sciences updates pipeline progress

Celgene discovers new TNF-alpha production inhibitors for cancer therapy

Aragen and Amorfix agree to co-develop cancer-targeting mAbs

FDA approves Photocure's Cysview for bladder cancer detection

German Health Agency sends official calendar for bilastine registration procedure

Cyberonics reports on postmarket VNS Therapy trial in depression

Synergy of ipilimumab and androgen ablation reported in prostate cancer

YM opens phase II nimotuzumab trial in patients with brain metastases from NSCLC

AstraZeneca and NIH's NIDDK collaborate to support DILIN

VaxGen to acquire diaDexus under revised merger agreement

Tesaro secures funds to acquire and develop cancer therapeutics

Noxxon Pharma raises funds for lead product development

ARCA launches phase I trial of GeoVax Labs' HIV vaccine

CytRx begins phase II bafetinib trial in B-cell chronic lymphocytic leukemia

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

Preclinical data demonstrate antileukemic effects of OXiGENE's OXi-4503

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...